Daniel J Wallace

Risk:benefit ratio of nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus

D. Wallace, Arash A Horizon, Daniel J Wallace, 2004, Expert opinion on drug safety.

Brain Magnetic Resonance Imaging in Newly Diagnosed Systemic Lupus Erythematosus

Peter T Fox, Michael H Weisman, Shalini Narayana, 2008, The Journal of Rheumatology.

Telomere diseases.

D. Wallace, Daniel J Wallace, 2010, The New England journal of medicine.

A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

G. Illei, D. Wallace, S. Manzi, 2003, Arthritis and rheumatism.

Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Gerald McGwin, Hong Fang, Caroline Gordon, 2012, Arthritis and rheumatism.

The frequency and outcome of lupus nephritis: results from an international inception cohort study.

Caroline Gordon, Paul Fortin, Kara Thompson, 2016, Rheumatology.

Retraction of the suggestion to use the term "Reiter's syndrome" sixty-five years later: the legacy of Reiter, a war criminal, should not be eponymic honor but rather condemnation.

D. Wallace, R. Panush, Daniel J Wallace, 2007, Arthritis and rheumatism.

Measurement of antinuclear antibodies by multiplex immunoassay: a prospective, multicenter clinical evaluation.

David L Buckeridge, Michael H Weisman, Mark H Wener, 2007, The Journal of rheumatology.